diagnosis
The most common presenting symptoms of a gastric MALT lymphoma are non-specific upper gastrointestinal complaints that often lead to an endoscopy usually revealing non-specific gastritis or peptic ulcer with mass lesions being unusual [2, 3] .
Diagnosis is based on the histopathological evaluation of the gastric biopsies [III, A] . The diagnosis should be in accordance with the current World Health Organisation (WHO) classification and accurate assessment of a potential associated large B-cell lymphoma is essential [4] . The diagnosis should, therefore, be confirmed by an expert haematopathologist [5] . It should be noted that the term 'high grade MALT lymphomas' is no longer accepted in the current WHO classification, hence cases with solid or sheet-like proliferation of transformed large cells have to be diagnosed as diffuse large B-cell lymphoma [4] . Differentiation from other indolent lymphomas is not always straightforward and a minimum immunohistochemistry panel should include CD20, CD10, CD5 and cyclin D1 [IV, B] . It is noteworthy that lymphoepithelial lesions, despite being very typical of MALT lymphoma, are neither essential for the diagnosis nor pathognomonic, as they can be seen under some reactive conditions as well as in other lymphoma subtypes.
If the presence of active H. pylori infection is not demonstrated by histochemistry, it must be ruled out by serology, urea breath test and/or stool antigen test [5, 6] .
In addition to routine histology and immunohistochemistry, fluorescence in situ hybridisation studies for detection of t(11;18) ( p21;p21) may be useful for identifying patients who are unlikely to respond to antibiotic therapy [III, B] [5, 6] .
staging and risk assessment
The question of which is the best system for the staging of gastric MALT lymphoma is controversial [2, 6] . The 'Lugano staging system' has been widely used in the past two decades, but more modern systems have been proposed, such as the 'Paris staging system', which describes more accurately the depth of gastric wall involvement, a parameter that may predict the lymphoma response to H. pylori eradication (Table 1) [7, 8] .
The initial staging procedures must include an esophagogastroduodenoscopy with multiple biopsies taken from each region of the stomach, duodenum and gastroesophageal junction and from any site with an abnormal appearance. Endoscopic ultrasound is recommended to evaluate the regional lymph nodes and gastric wall infiltration [III, A] [2, 3, 5, 6, 9] . Work-up studies should include history and physical examination, including lymph node regions, eye and ear, nose and throat areas, liver and spleen evaluation; complete blood counts, basic biochemical studies, which may include evaluation of renal and liver function, lactate dehydrogenase and β2-microglobulin, serum protein immunofixation, human immunodeficiency virus, hepatitis C virus and hepatitis B virus serology, computed tomography scan of the chest, abdomen and pelvis [IV, B] 
treatment plan
Helicobacter pylori eradication therapy must be given to all gastric MALT lymphomas, independently of stage [5] . Antihelicobacter regimens combining proton-pump inhibitor (PPI) plus clarithromycin-based triple therapy with either amoxicillin or metronidazole for 10-14 days are usually highly effective [10] . The outcome of the eradication therapy should be checked by a urea breath test (or by a monoclonal stool antigen test) at least 6 weeks after eradication therapy and at least 2 weeks after PPI withdrawal. In case of unsuccessful H. pylori eradication, a second-line therapy should be attempted with alternative tripleor quadruple-therapy regimens of PPI plus antibiotics [1, 6] .
Eradication of H. pylori with antibiotics should be the sole initial therapy for a localised H. pylori-positive gastric MALT lymphoma, where this treatment can induce lymphoma regression and long-term clinical disease control in most patients [II, A]. The length of time necessary to obtain a remission can span from very few months to >12 months. It is reasonable to wait for at least 12 months before starting another treatment in patients who achieve a clinical and endoscopic remission together with eradication of H. pylori, albeit having persistent (residual) lymphoma at the histological level [III, B] [6] . Several studies of post-antibiotic molecular follow-up have shown the frequent persistence of monoclonal B-cells after histological regression of the lymphoma [1, 6] .
In H. pylori-negative cases, a regression of the lymphoma after antibiotic treatment is unlikely and the immediate start of oncological treatments (see below) should be considered, but the administration of an anti-helicobacter regimen may be worthwhile since occasional lymphoma responses have been reported (possibly due to a false-negative test or to infection by other Helicobacter species) [6] . In these H. pylori-negative patients, an oncological treatment (usually radiotherapy as described below) should, however, be considered if no signs of lymphoma regression are seen at a repeat endoscopy assessment 2 to 3 months after antibiotics administration [6] .
In patients who do not achieve a lymphoma regression following antibiotic therapy, irradiation and systemic oncological therapies should be applied depending on the stage of disease. Radiotherapy might be the preferred option for localised stage. Excellent disease control using radiation therapy alone has been reported by several institutions supporting the use of moderate-dose involved-field radiotherapy (24-30 Gy radiation to the stomach and perigastric nodes given in 3 to 4 weeks) [III, B] [11, 12] .
Chemotherapy and/or immunotherapy are effective in patients with MALT lymphoma of all stages. Chemoimmunotherapy should be preferred in case of histological transformation, contraindications to radiotherapy, and vice versa. However, there is no definitive evidence to guide the choice between radiotherapy and systemic treatment in localised gastric MALT lymphoma, which depends very much on the local expertise of the attending physicians [1, 5] . Patients with t(11;18) will most probably be unresponsive to alkylating agents as a sole treatment [1, 6] . Surgery has not been shown to achieve superior results in comparison with more conservative approaches in various trials. It may impair the quality of life and no longer has a role in the initial treatment [13] .
Patients with symptomatic systemic disease should be considered for systemic treatment [III, A]. As in other disseminated low-grade lymphomas, rituximab plus chemotherapy would then be the most appropriate choice when treatment is needed. T1-4 N0-3 M2 T1-4 N0-3 M0-2 BX T1-4 N0-3 M0-2 B0 T1-4 N0-3 M2 B1 Figure 1 . Treatment algorithms for either localised or advanced gastric MALT lymphoma (stage is defined according to the Lugano system described in Table 1 ).
clinical practice guidelines
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Only a few compounds and regimens have been tested specifically in MALT lymphomas. Oral alkylating agents (either cyclophosphamide or chlorambucil) or purine nucleoside analogues (fludarabine, cladribine) and the combination of rituximab and bendamustine have shown a high rate of disease control in non-randomised studies. The activity of rituximab has also been demonstrated in phase II studies [14] and its efficacy in combination with chlorambucil has been proven in a randomised study [II, A] [15] . This combination was very welltolerated but no overall survival benefit has been shown [15] and there is not yet an accepted standard chemotherapy to be recommended. It should, however, be mentioned that treatment with purine analogues might be associated with an increased risk of secondary myelodysplasia. There are no data supporting a rituximab maintenance strategy. Aggressive anthracyclinecontaining regimens are not usually necessary and should be reserved for the few patients with a very aggressive clinical course or histological transformation [3] . Treatment algorithms summarising the above discussed management strategies for either localised or advanced gastric MALT lymphoma are shown in Figure 1 .
personalised medicine
Absence of H. pylori, deep invasion of the gastric wall (beyond the sub-mucosa), regional lymph node involvement, the presence of chromosomal translocations that result in deregulation of MALT1 or Bcl-10 and other genetic features (such as overexpression of miR-142-5p and miR-155) can be associated with a reduced probability of lymphoma regression after antibiotics [1] [2] [3] [16] [17] [18] . As discussed above, detection of t (11;18) may also help to distinguish patients who may not respond to alkylating agents alone. Nevertheless, in this disease setting, more research is needed to identify molecular markers which could lead to advances in personalised medicine.
response evaluation and follow-up
Histological evaluation of repeat biopsies remains an essential follow-up procedure to exclude either the possibility of persistent significant disease or, particularly in patients with persistent H. pylori infection, the appearance of early epithelial changes, which may be related to gastric carcinoma. Unfortunately, the interpretation of lymphoid infiltrate in posttreatment gastric biopsies can be very difficult and there are no uniform criteria for the definition of histological remission. Comparison with previous biopsies should be carried out to assess response, and we recommend the GELA (Group d'Etude des Lymphomes de l'Adult) scoring system (Table 2) as a reproducible method [IV, B] [19] .
Following the documentation of the achieved H. pylori eradication, a strict endoscopic follow-up is recommended, with multiple biopsies taken 2 to 3 months after treatment to rule out tumour progression, and subsequently (twice per year for 2 years) to monitor the histological regression of the lymphoma.
Gastric MALT lymphomas have a limited tendency to distant spreading and to histological transformation. Transient, apparent histological relapses are occasionally observed in endoscopic follow-up biopsies, but they have to be sustained and progressive in order to be considered a relapse, as they tend to be self-limiting, especially in the absence of H. pylori reinfection. Hence, in the case of persistent but stable residual disease or histological relapse (without distant dissemination and/or gross endoscopic tumour), a watch-and-wait policy appears to be safe [IV, C] [16, [20] [21] [22] . Nevertheless, a long-term careful endoscopic and systemic follow-up (clinical examination, blood counts and minimal adequate radiological or ultrasound examinations every 12-18 months) is recommended for all patients. Indeed, the risk of gastric adenocarcinoma among patients diagnosed with gastric MALT lymphomas has been reported to be sixfold higher than in the general population [23] and also the risk of other nonHodgkin's lymphomas may be increased [24] .
note Levels of evidence and grades of recommendation have been applied using the system shown in Table 3 . Statements without grading were considered justified standard clinical practice by the experts and the ESMO faculty.
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